Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of "Hold" by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have received a consensus rating of "Hold" from the twenty brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $111.39.

A number of analysts have weighed in on the stock. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. JMP Securities decreased their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Raymond James Financial dropped their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, Morgan Stanley dropped their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of ZBH. Garde Capital Inc. purchased a new stake in Zimmer Biomet in the first quarter valued at $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Columbia River Financial Group LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Menard Financial Group LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at approximately $30,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

NYSE:ZBH traded down $0.48 during trading hours on Thursday, reaching $96.85. 1,234,505 shares of the company were exchanged, compared to its average volume of 1,929,018. The stock's 50-day moving average is $93.19 and its 200-day moving average is $100.68. The firm has a market cap of $19.16 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 2.27 and a beta of 0.71. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet has a twelve month low of $89.22 and a twelve month high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. Zimmer Biomet's revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.94 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.99%. Zimmer Biomet's payout ratio is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.